PET in Breast Cancer Receiving Neoadjuvant Chemotherapy

• Status: Completed
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

Prognostic factors in locally advanced breast cancer treated with neoadjuvant chemotherapy differ from those of early breast cancer.

The purpose of this study was to identify the clinical significance of potential predictive and prognostic factors including serial FDG PET/CT in breast cancer patients treated by neoadjuvant chemotherapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Docetaxel; Doxorubicin; Liposomal doxorubicin

Criteria

Inclusion Criteria:

1. pathologically-confirmed breast cancer by core needle biopsy,

2. initial clinical stage II or III,

3. objective measurable lesion,

4. ECOG performance 0~2,

5. previously untreated,

6. adequate bone marrow, hepatic, cardiac, and renal functions

7. age 20~70

8. agreement with this trial, and written informed consent

Exclusion Criteria:

1. history of other cancer

2. active infection

3. pregnancy

4. psychologic disease

5. uncontrolled heart diseases

6. male